lyxumia solution for injection in pre-filled pen 20mcg (100mcgml)
sanofi-aventis singapore pte. ltd. - lixisenatide - injection, solution - 100mcg/ml - lixisenatide 100mcg/ml
bydureon 2mg powder and solvent for prolonged-release suspension for injection vials
lexon (uk - exenatide - powder and solvent for prolonged-release suspension for inj - 2mg
byetta s.c.injection 10mcg pen 300 (バイエッタ皮下注10μgペン300)
astrazeneca k.k - exenatide - clear and colorless injectable preparation
byetta s.c.injection 5mcg pen 300 (バイエッタ皮下注5μgペン300)
astrazeneca k.k - exenatide - clear and colorless injectable preparation
lyxumia
sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.
lyxumia
sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.
lyxumia
sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.
lyxumia lixisenatide 10 mcg (0.05mg/ml) solution for injection injector pen
sanofi-aventis australia pty ltd - lixisenatide -
lyxumia treatment initiation pack 10mcg (0.05 mg/ml) and 20 mcg (0.1) mg/ml solution for injection injector pen
sanofi-aventis australia pty ltd - lixisenatide -
lixisenatide sanofi treatment initiation pack 10mcg (0.05 mg/ml) and 20 mcg (0.1) mg/ml solution for injection injector pen
sanofi-aventis australia pty ltd - lixisenatide -